These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33436015)

  • 1. Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity.
    Liu Y; Xu J; Wu M; Xu B; Kang L
    Lipids Health Dis; 2021 Jan; 20(1):5. PubMed ID: 33436015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model.
    Liu Y; Wu M; Xu B; Kang L
    J Inflamm Res; 2021; 14():2277-2287. PubMed ID: 34103961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
    Pennig J; Scherrer P; Gissler MC; Anto-Michel N; Hoppe N; Füner L; Härdtner C; Stachon P; Wolf D; Hilgendorf I; Mullick A; Bode C; Zirlik A; Goldberg IJ; Willecke F
    Sci Rep; 2019 Nov; 9(1):17937. PubMed ID: 31784656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice.
    Dimitriadis GK; Nasiri-Ansari N; Agrogiannis G; Kostakis ID; Randeva MS; Nikiteas N; Patel VH; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Mol Cell Endocrinol; 2019 Aug; 494():110487. PubMed ID: 31195080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE
    Han JH; Oh TJ; Lee G; Maeng HJ; Lee DH; Kim KM; Choi SH; Jang HC; Lee HS; Park KS; Kim YB; Lim S
    Diabetologia; 2017 Feb; 60(2):364-376. PubMed ID: 27866224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role.
    Fu J; Xu H; Wu F; Tu Q; Dong X; Xie H; Cao Z
    Int J Cardiol; 2022 Nov; 367():56-62. PubMed ID: 35931206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy.
    Xu H; Fu J; Tu Q; Shuai Q; Chen Y; Wu F; Cao Z
    J Physiol Biochem; 2024 Feb; 80(1):27-39. PubMed ID: 37792168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes.
    Gueguen C; Burke SL; Barzel B; Eikelis N; Watson AMD; Jha JC; Jackson KL; Sata Y; Lim K; Lambert GW; Jandeleit-Dahm KAM; Cooper ME; Thomas MC; Head GA
    Diabetologia; 2020 Jul; 63(7):1424-1434. PubMed ID: 32372207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
    Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
    Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
    Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
    Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr
    Al-Sharea A; Murphy AJ; Huggins LA; Hu Y; Goldberg IJ; Nagareddy PR
    Atherosclerosis; 2018 Apr; 271():166-176. PubMed ID: 29518749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
    Jordan J; Tank J; Heusser K; Heise T; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
    J Am Soc Hypertens; 2017 Sep; 11(9):604-612. PubMed ID: 28757109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
    Schork A; Saynisch J; Vosseler A; Jaghutriz BA; Heyne N; Peter A; Häring HU; Stefan N; Fritsche A; Artunc F
    Cardiovasc Diabetol; 2019 Apr; 18(1):46. PubMed ID: 30953516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation inhibition and gut microbiota regulation by TSG to combat atherosclerosis in ApoE
    Li F; Zhang T; He Y; Gu W; Yang X; Zhao R; Yu J
    J Ethnopharmacol; 2020 Jan; 247():112232. PubMed ID: 31606534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
    Kidokoro K; Cherney DZI; Bozovic A; Nagasu H; Satoh M; Kanda E; Sasaki T; Kashihara N
    Circulation; 2019 Jul; 140(4):303-315. PubMed ID: 30773020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes.
    Heise T; Jordan J; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
    Clin Ther; 2016 Oct; 38(10):2265-2276. PubMed ID: 27692976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.
    Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T
    PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
    Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M
    Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE
    Leng W; Ouyang X; Lei X; Wu M; Chen L; Wu Q; Deng W; Liang Z
    Mediators Inflamm; 2016; 2016():6305735. PubMed ID: 28104929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.